Quantcast

Latest Cancer treatments Stories

2013-12-12 10:58:07

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium. The findings offer, for the first time, a set of standard treatment guidelines for...

2013-12-11 12:07:24

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "Worldwide, anthracyclines such as doxorubicin [Adriamycin] and epirubicin have...

2013-12-11 12:05:10

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "We have previously shown that high levels of tumor-infiltrating lymphocytes [immune cells in a tumor] are predictive of response to trastuzumab and chemotherapy administered after surgery for early-stage,...

2013-12-11 12:02:49

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14. "NeoALTTO is a randomized, phase III clinical trial evaluating whether a combination of two HER2-targeted therapies, trastuzumab and lapatinib, given with standard paclitaxel chemotherapy before...

Engineered Immune Cells Fight Cancer
2013-12-09 14:30:13

Brett Smith for redOrbit.com - Your Universe Online Researchers from the University of Pennsylvania and the Children’s Hospital of Philadelphia have been able to reprogram the body’s immune system to fight leukemia, with 89 percent of children and adults in a series of clinical trials showing no evidence of cancer after receiving a personalized cell therapy. The findings from the first 59 patients to receive this cutting-edge therapy, known as CTL019, were presented during the...

2013-12-06 11:13:12

Researchers describe a novel mechanism by which glioblastoma tumors resist targeted therapies A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma (GBM), the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.